Skip to main content

Romina Dieli Crimi

Institutions of which they are part

Translational Immunology
Vall Hebron Institut de Recerca

Romina Dieli Crimi

Institutions of which they are part

Translational Immunology
Vall Hebron Institut de Recerca

Projects

Desarrollo de tests rápidos intercambiables para el control multifacético de las infecciones respiratorias

IP: Eva Baldrich Rubio
Collaborators: Romina Dieli Crimi, Cristina Andrés Vergés
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 141875
Reference: PID2023-148950OB-C22
Duration: 01/09/2024 - 31/12/2027

Ministerio de Ciencia

Identification and functional characterization of structural variants in patients with inborn errors of immunity

IP: Roger Colobran Oriol
Collaborators: Romina Dieli Crimi, Aina Aguiló Cucurull, Laura Batlle Masó, Andrea Martín Nalda, Neus Castells Sarret
Funding agency: Instituto de Salud Carlos III
Funding: 208750
Reference: PI23/00161
Duration: 01/01/2024 - 31/12/2026

COVID-19, PERFIL INMUNOLÓGICO DE RIESGO

IP: -
Collaborators: Manuel Hernández González, Mónica Martínez Gallo, Moisés Labrador Horrillo, Gema Codina Grau, Albert Blanco Grau, Andres Antón Pagarolas, Antonio Álvarez Fernandez, Nuria Fernández Hidalgo, Roser Ferrer Costa, Esteve Ribera Pascuet, Juan Carlos Ruiz Rodriguez, Jaume Ferrer Sancho, Anna Suy Franch, Pere Soler Palacín, Albert Selva O'Callaghan, Tomàs Pumarola Suñé, Isabel Ruiz Camps, Daniel Alvarez De la Sierra, Andrea Martín Nalda, Eva Polverino, Romina Dieli Crimi, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 229000
Reference: COV20/00416
Duration: 08/05/2020 - 08/11/2021

Synthetic diagnostic device to substitute animal erythrocytes in classical haemagglutination assays: application to influenza virus surveillance.

IP: Eva Baldrich Rubio
Collaborators: Romina Dieli Crimi, Mónica Martínez Gallo, Andres Antón Pagarolas, Tomàs Pumarola Suñé, Cristina Andrés Vergés
Funding agency: Instituto de Salud Carlos III
Funding: 104500
Reference: DTS20/00093
Duration: 01/01/2021 - 30/06/2023

Related news

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

A study from the Vall d’Hebron Campus demonstrates that the Ex Vivo C5b-9 deposition test is useful for monitoring the activity of the complement system (CS) in patients with aHUS or transplant-associated TMA.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

Related professionals

Mª Teresa Fernández Taranilla

Mª Teresa Fernández Taranilla

Administration and Management
Cardiovascular Diseases
Read more
Albert Selva O'Callaghan

Albert Selva O'Callaghan

Main researcher
Systemic Diseases
Read more
Anna Vilarrodona Serrat

Anna Vilarrodona Serrat

Main researcher
Donation and transplantation of organs, tissues and cells
Read more
M Jesus Arevalo  Navines

M Jesus Arevalo Navines

Postdoctoral researcher
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.